KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Encompass Health (EHC) Cash & Equivalents (2016 - 2026)

Encompass Health (EHC) has disclosed Cash & Equivalents for 18 consecutive years, with $110.5 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 15.34% year-over-year to $110.5 million; the TTM value through Mar 2026 reached $110.5 million, up 15.34%, while the annual FY2025 figure was $72.2 million, 15.46% down from the prior year.
  • Cash & Equivalents hit $110.5 million in Q1 2026 for Encompass Health, up from $72.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $154.4 million in Q2 2024 and bottomed at $21.8 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $94.9 million, with a median of $95.8 million recorded in 2025.
  • Year-over-year, Cash & Equivalents surged 216.97% in 2023 and then plummeted 67.05% in 2025.
  • Encompass Health's Cash & Equivalents stood at $21.8 million in 2022, then soared by 216.97% to $69.1 million in 2023, then increased by 23.59% to $85.4 million in 2024, then fell by 15.46% to $72.2 million in 2025, then soared by 53.05% to $110.5 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $110.5 million, $72.2 million, and $48.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.